SecProbe.io

<DOCUMENT>
<TYPE>LETTER
<SEQUENCE>1
<FILENAME>filename1.txt
<TEXT>
Mail Stop 7010
      June 13, 2005

Mr. Barry E. Stewart, Chief Financial Officer
Rotech Healthcare, Inc.
2600 Technology Drive, Suite 300
Orlando, FL 32804

      Re:	Rotech Healthcare, Inc.
      Form 8-K Filed on June 9, 2005
		File No. 0-50940

Dear Mr. Stewart:

	We have reviewed your Item 4.02 Form 8-K for compliance with
the
form requirements and have the following comment.
1. You have disclosed that you intend to file restated financial
statements.  However, you have not indicated how or when you
intend
to do so.  Please tell us how and when you intend to file restated
financial statements.  We may have further comments after you file
the restated financial statements.

We remind you that when you file your restated Form 10-K you
should
appropriately address the following:
* an explanatory paragraph in the reissued audit opinion,
* full compliance with APB 20, paragraphs 36 and 37,
* fully update all affected portions of the document, including
MD&A,
selected financial data, and quarterly financial data,
* updated Item 9A. disclosures should include the following:
o a discussion of the restatement and the facts and circumstances
surrounding it,
o how the restatement impacted the CEO and CFO`s original
conclusions
regarding the effectiveness of their disclosure controls and
procedures,
o changes to internal controls over financial reporting, and
o anticipated changes to disclosure controls and procedures and/or
internal controls over financial reporting to prevent future
misstatements of a similar nature.
Refer to Items 307 and 308(c) of Regulation S-K.
* include all updated certifications.

      Please respond to this comment within 5 business days, or
tell
us when you will provide us with a response.  Please provide us
with
a response letter that keys your response to our comment and
provides
any requested information.  Detailed letters greatly facilitate
our
review.  Please file your response on EDGAR as a correspondence
file.
Please understand that we may have additional comments after
reviewing your response to our comment.

      We urge all persons who are responsible for the accuracy and
adequacy of the disclosure in the filings reviewed by the staff to
be
certain that they have provided all information investors require
for
an informed decision.  Since the company and its management are in
possession of all facts relating to a company`s disclosure, they
are
responsible for the accuracy and adequacy of the disclosures they
have made.

	In connection with responding to our comments, please
provide,
in writing, a statement from the company acknowledging that:
* the company is responsible for the adequacy and accuracy of the
disclosure in their filings;
* staff comments or changes to disclosure in response to staff
comments do not foreclose the Commission from taking any action
with
respect to the filing; and
* the company may not assert staff comments as a defense in any
proceeding initiated by the Commission or any person under the
federal securities laws of the United States.

		In addition, please be advised that the Division of
Enforcement has access to all information you provide to the staff
of
the Division of Corporation Finance in our review of your filing
or
in response to our comments on your filing.

	You may contact Bret Johnson at (202) 551-3753 or me at (202)
551-3255 if you have questions regarding our comment.

							Sincerely,

							Nili Shah
							Accounting Branch Chief
??

??

??

??

Barry E. Stewart
Rotech Healthcare, Inc.
June 13, 2005
Page 1

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549-7010

         DIVISION OF
CORPORATION FINANCE

</TEXT>
</DOCUMENT>